269 related articles for article (PubMed ID: 34076991)
21. Genetic and pharmacological inhibition of METTL3 alleviates renal fibrosis by reducing EVL m6A modification through an IGF2BP2-dependent mechanism.
Ni WJ; Zhou H; Lu H; Ma NN; Hou BB; Li W; Kong FX; Yu JT; Hou R; Jin J; Wen JG; Zhang T; Meng XM
Clin Transl Med; 2023 Aug; 13(8):e1359. PubMed ID: 37537731
[TBL] [Abstract][Full Text] [Related]
22. Changes of N6-methyladenosine modulators promote breast cancer progression.
Wu L; Wu D; Ning J; Liu W; Zhang D
BMC Cancer; 2019 Apr; 19(1):326. PubMed ID: 30953473
[TBL] [Abstract][Full Text] [Related]
23. Methyltransferase-like 3 facilitates the stem cell properties of esophageal cancer by upregulating patched homolog 1 via N6-methyladenosine methylation.
Liang H; Fang C; Zhang L
Am J Physiol Cell Physiol; 2023 Sep; 325(3):C770-C779. PubMed ID: 37575058
[TBL] [Abstract][Full Text] [Related]
24. METTL3 promotes pancreatic cancer proliferation and stemness by increasing stability of ID2 mRNA in a m6A-dependent manner.
Chen J; Zhang H; Xiu C; Gao C; Wu S; Bai J; Shen Q; Yin T
Cancer Lett; 2023 Jul; 565():216222. PubMed ID: 37196908
[TBL] [Abstract][Full Text] [Related]
25. The m6A methyltransferase METTL3 promotes osteosarcoma progression by regulating the m6A level of LEF1.
Miao W; Chen J; Jia L; Ma J; Song D
Biochem Biophys Res Commun; 2019 Aug; 516(3):719-725. PubMed ID: 31253399
[TBL] [Abstract][Full Text] [Related]
26. Cross talk between RNA N6-methyladenosine methyltransferase-like 3 and miR-186 regulates hepatoblastoma progression through Wnt/β-catenin signalling pathway.
Cui X; Wang Z; Li J; Zhu J; Ren Z; Zhang D; Zhao W; Fan Y; Zhang D; Sun R
Cell Prolif; 2020 Mar; 53(3):e12768. PubMed ID: 31967701
[TBL] [Abstract][Full Text] [Related]
27. Methyltransferase-like 3 promotes cervical cancer metastasis by enhancing cathepsin L mRNA stability in an N6-methyladenosine-dependent manner.
Liu P; Ju M; Zheng X; Jiang Y; Yu X; Pan B; Luo R; Jia W; Zheng M
Cancer Sci; 2023 Mar; 114(3):837-854. PubMed ID: 36382580
[TBL] [Abstract][Full Text] [Related]
28. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2.
Chen M; Wei L; Law CT; Tsang FH; Shen J; Cheng CL; Tsang LH; Ho DW; Chiu DK; Lee JM; Wong CC; Ng IO; Wong CM
Hepatology; 2018 Jun; 67(6):2254-2270. PubMed ID: 29171881
[TBL] [Abstract][Full Text] [Related]
29. METTL3 promotes prostate cancer progression by regulating miR-182 maturation in m6A-dependent manner.
Wang D; Wang X; Huang B; Zhao Y; Tu W; Jin X; Shao Y; Zhu Y; Lu G
Andrologia; 2022 Aug; 54(7):1581-1591. PubMed ID: 35413135
[TBL] [Abstract][Full Text] [Related]
30. The N6-methyladenosine METTL3 regulates tumorigenesis and glycolysis by mediating m6A methylation of the tumor suppressor LATS1 in breast cancer.
Xu Y; Song M; Hong Z; Chen W; Zhang Q; Zhou J; Yang C; He Z; Yu J; Peng X; Zhu Q; Li S; Ji K; Liu M; Zuo Q
J Exp Clin Cancer Res; 2023 Jan; 42(1):10. PubMed ID: 36609396
[TBL] [Abstract][Full Text] [Related]
31. METTL3 promotes the growth and metastasis of pancreatic cancer by regulating the m6A modification and stability of E2F5.
Tang Y; Gao G; Xia WW; Wang JB
Cell Signal; 2022 Nov; 99():110440. PubMed ID: 35985439
[TBL] [Abstract][Full Text] [Related]
32. The "m6A writer" METTL3 and the "m6A reader" IGF2BP2 regulate cutaneous T-cell lymphomas progression via CDKN2A.
Wang X; Hu M; Yu L; Wang X; Jiang X; Zhang G; Ding K
Hematol Oncol; 2022 Oct; 40(4):567-576. PubMed ID: 35446451
[TBL] [Abstract][Full Text] [Related]
33. Methyltransferase-like 3 (METTL3) mediated N6-methyladenosine (m6A) modifications facilitate mir-25-3p maturation to promote gastrointestinal stromal tumors (GISTs) progression.
Qian K; Xu W; Xia X; Ding J
Genes Genomics; 2022 Dec; 44(12):1519-1530. PubMed ID: 36040683
[TBL] [Abstract][Full Text] [Related]
34. METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression.
Guo YQ; Wang Q; Wang JG; Gu YJ; Song PP; Wang SY; Qian XY; Gao X
Exp Hematol Oncol; 2022 Mar; 11(1):14. PubMed ID: 35287752
[TBL] [Abstract][Full Text] [Related]
35. The m
Cheng M; Sheng L; Gao Q; Xiong Q; Zhang H; Wu M; Liang Y; Zhu F; Zhang Y; Zhang X; Yuan Q; Li Y
Oncogene; 2019 May; 38(19):3667-3680. PubMed ID: 30659266
[TBL] [Abstract][Full Text] [Related]
36. METTL3 m6A-dependently promotes miR-21-5p maturation to accelerate choriocarcinoma progression via the HIF1AN-induced inactivation of the HIF1A/VEGF pathway.
Ye K; Li L; Wu B; Wang D
Genes Genomics; 2022 Nov; 44(11):1311-1322. PubMed ID: 36074324
[TBL] [Abstract][Full Text] [Related]
37. SUMO1 modification of methyltransferase-like 3 promotes tumor progression via regulating Snail mRNA homeostasis in hepatocellular carcinoma.
Xu H; Wang H; Zhao W; Fu S; Li Y; Ni W; Xin Y; Li W; Yang C; Bai Y; Zhan M; Lu L
Theranostics; 2020; 10(13):5671-5686. PubMed ID: 32483411
[No Abstract] [Full Text] [Related]
38. The m6A methyltransferase METTL3 controls epithelial-mesenchymal transition, migration and invasion of breast cancer through the MALAT1/miR-26b/HMGA2 axis.
Zhao C; Ling X; Xia Y; Yan B; Guan Q
Cancer Cell Int; 2021 Aug; 21(1):441. PubMed ID: 34419065
[TBL] [Abstract][Full Text] [Related]
39. METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1.
Ai Y; Liu S; Luo H; Wu S; Wei H; Tang Z; Li X; Lv X; Zou C
J Immunol Res; 2021; 2021():6149558. PubMed ID: 34476262
[TBL] [Abstract][Full Text] [Related]
40. METTL3/YTHDF2 m6A axis accelerates colorectal carcinogenesis through epigenetically suppressing YPEL5.
Zhou D; Tang W; Xu Y; Xu Y; Xu B; Fu S; Wang Y; Chen F; Chen Y; Han Y; Wang G
Mol Oncol; 2021 Aug; 15(8):2172-2184. PubMed ID: 33411363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]